Benchmark Capital Advisors’s Celldex Therapeutics CLDX Stock Holding History

Benchmark Capital Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$6K	Sell	2,173 -1,387	-39%	-$6.81K	0.01%	114
2018 Q3	$24K	Sell	3,560 -67	-2%	-$469	0.02%	133
2018 Q2	$27K	Sell	3,627 -40	-1%	-$535	0.02%	129
2018 Q1	$128K	Sell	3,667 -400	-10%	-$15.5K	0.1%	123
2017 Q4	$173K	Sell	4,067 -253	-6%	-$10.8K	0.14%	121
2017 Q3	$185K	Hold	4,320	–	–	0.14%	125
2017 Q2	$160K	Hold	4,320	–	–	0.13%	123
2017 Q1	$234K	Sell	4,320 -133	-3%	-$6.93K	0.18%	102
2016 Q4	$236K	Sell	4,453 -14	-0.3%	-$796	0.2%	100
2016 Q3	$271K	Hold	4,467	–	–	0.2%	99
2016 Q2	$294K	Sell	4,467 -366	-8%	-$23.2K	0.24%	92
2016 Q1	$274K	Buy	4,833 +3,490	+260%	+$393K	0.24%	89
2015 Q4	$316K	Buy	+1,343	New	+$293K	0.27%	79

Other funds holding CLDX

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Benchmark Capital Advisors's CLDX Position: Q4 2018 in Review

Benchmark Capital Advisors reduced its Celldex Therapeutics (CLDX) stake by 39% in Q4 2018, selling an estimated $6.81K and leaving 2,173 shares worth $6K. The position accounts for 0.01% of the portfolio, ranked #114.

Benchmark Capital Advisors first reported a position in CLDX in Q4 2015 and has held it in 13 quarters since. The position peaked at $316K in Q4 2015. 85 funds tracked by Wall St. Rank hold CLDX as of Q4 2018.

Benchmark Capital Advisors held 2,173 shares of Celldex Therapeutics worth $6K as of Q4 2018.
Benchmark Capital Advisors sold 1,387 Celldex Therapeutics shares in Q4 2018, an estimated $6.81K.
Celldex Therapeutics made up 0.01% of Benchmark Capital Advisors's portfolio in Q4 2018, its #114 holding.
Benchmark Capital Advisors first reported a position in Celldex Therapeutics in Q4 2015 and has held it in 13 quarters since.
Benchmark Capital Advisors's Celldex Therapeutics position peaked at $316K in Q4 2015.
85 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2018.

Based on Benchmark Capital Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.